Aug 28, 2024
|
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
|
|
Aug 06, 2024
|
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
|
|
Jul 31, 2024
|
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
|
|
Jul 25, 2024
|
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
|
|
Jul 16, 2024
|
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
|
|
May 28, 2024
|
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
|
|
May 13, 2024
|
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
|
|
May 13, 2024
|
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
|
|
Mar 14, 2024
|
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
|
|
Feb 22, 2024
|
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
|
|